Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB with OMV + MenACWY Combination Vaccination Formulations.

Trial Profile

Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB with OMV + MenACWY Combination Vaccination Formulations.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group B OMV Novartis
  • Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 27 Oct 2011 Additional location (Poland) and actual initiaton date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 27 Oct 2011 Planned End Date changed from 1 Jul 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 27 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top